OmniComm’s eClinical Suite, including the EDC, CTMS, Safety, and Coding solutions, will be used to collect, process, and analyze patient data and adverse events throughout the life of each trial.
OmniComm clinical research and development vice president Joel Melnick said, "The integrated suite of EDC, CTMS, and Safety has streamlined our processes and allows us to focus on executing the trials."
Both of these 30 site, Phase III studies are evaluating the efficacy and safety of CTAP101 Capsules to treat secondary hyperparathyroidism in subjects with stage 3 Chronic Kidney Disease (CKD) and vitamin D insufficiency.
OmniComm president and COO Stephen Johnson said,"We appreciate their ongoing trust in us and will continue to deliver superior products and services to them as they strive to bring life-changing drugs to market."